Brown, P. A., Kairalla, J. A., Hilden, J. M., Dreyer, Z. E., Carroll, A. J., Heerema, N. A., . . . Hunger, S. P. (2021). FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631. Leukemia, 35(5), 1279-1290. https://doi.org/10.1038/s41375-021-01177-6
Citace podle Chicago (17th ed.)Brown, Patrick A., et al. "FLT3 Inhibitor Lestaurtinib Plus Chemotherapy for Newly Diagnosed KMT2A-rearranged Infant Acute Lymphoblastic Leukemia: Children’s Oncology Group Trial AALL0631." Leukemia 35, no. 5 (2021): 1279-1290. https://doi.org/10.1038/s41375-021-01177-6.
Citace podle MLA (9th ed.)Brown, Patrick A., et al. "FLT3 Inhibitor Lestaurtinib Plus Chemotherapy for Newly Diagnosed KMT2A-rearranged Infant Acute Lymphoblastic Leukemia: Children’s Oncology Group Trial AALL0631." Leukemia, vol. 35, no. 5, 2021, pp. 1279-1290, https://doi.org/10.1038/s41375-021-01177-6.